Low-Dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: A randomized controlled trial Academic Article uri icon

Overview

MeSH Major

  • Antiretroviral Therapy, Highly Active
  • HIV Infections
  • Interleukin-2

abstract

  • Daily, low-dose subcutaneous IL-2 therapy in conjunction with HAART is safe and well tolerated and is effective in expanding lymphocyte cell types including NK cells and naive T cells in individuals who have <300 CD4+ T cells.

publication date

  • December 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11590500

Additional Document Info

start page

  • 1

end page

  • 15

volume

  • 1

number

  • 3